Nest.Bio Ventures

Nest.Bio Ventures generates proprietary deal flow through its own lab infrastructure. The firm operates Nest.Bio Labs and Hatch.Bio Labs in Kendall Square, Cambridge, where resident biotech companies lease shared or private wet-lab and office space. The proximity lets the investment team observe company progress directly and move early on equity positions in the most promising tenants. External startups are considered, but the resident-graduate funnel forms the core of its sourcing model.

Nest.Bio Ventures makes direct equity investments in early-stage biotechnology and therapeutics companies. The firm’s public materials describe a model where it works alongside founders to develop, fund, and commercialize their technologies, with no mention of participating as a limited partner in third-party venture funds. The structure centers on direct, company-level exposure sourced predominantly from its resident-company pipeline.

Nest.Bio Ventures covers a broad range from seed and start-up through growth and late-stage venture, with a clear tilt toward the earliest stages. The firm’s resident companies span early-stage R&D through expansion-stage enterprises, and its own capital is deployed flexibly along that curve. The incubator environment naturally emphasizes formation-stage therapeutics companies, which can access both lab infrastructure and first institutional capital through the platform.

The firm lists Partners James Weis, Cheryl Cui, Hingge Hsu, and Daphne Teo as the core investment leadership, supported by Venture Partners Xi Chen, Steven Landau, and Jeffrey Lu. The public team page does not specify an investment committee or indicate whether decisions require unanimity among the Partners. The concentrated partner group suggests investment approvals remain with this small group of named principals.

Nest.Bio Ventures is structured as a private-equity asset manager, not a family office. No public disclosure ties the firm’s capital to a single-family wealth source. Its investment activities are administered by a partnership group, and its lab real estate operates under a separate but affiliated vehicle, Hatch.Bio Labs, with its own business development leadership and site-management team.

Nest.Bio Labs and its successor brand Hatch.Bio Labs provide shared and private wet-lab and office space to resident biotech startups. Nest.Bio Ventures is the affiliated investment entity that selects a subset of those startups for direct equity funding. James Weis is CEO of both the lab operations and the venture entity, and the websites are hosted on a single nest.bio domain, signaling integrated governance even as the lab and venture activities remain operationally distinct.

The firm’s public materials do not reference any philanthropic foundation, donor-advised fund, or non-profit entity attached to Nest.Bio Ventures or its lab operations. The entire platform appears commercially oriented, focused on for-profit biotech incubation and direct venture investing.